Niosomal Formulation for Co-Administration of Hydrophobic Anticancer Drugs into MCF-7 Cancer Cells
Archives of Advances in Biosciences,
Vol. 11 No. 2 (2020),
16 May 2020
,
Page 1-9
https://doi.org/10.22037/aab.v11i2.28906
Abstract
Introduction: Designing and developing drug delivery systems has received tremendous attention during the last decade. The treatment of cancer cells is a complicated process due to the existence of different biological pathways. Therefore, the co-delivery of different drugs could have a synergic effect on the treatment process.
Materials and Methods: In this study, different types of span (20, 60, 80) and cholesterol were utilized to formulate tamoxifen/curcumin co-loaded niosomes as a drug carrier system for breast cancer chemotherapy. Niosome characterization was performed through a set of instrument analysis techniques including scanning electron microscopy (SEM) and dynamic light scattering. Release behavior was studied by dialysis method at (pH = 5, 7.4). The stability was monitored during two months storage at two temperatures (4 and 25 °C). Cytotoxicity activity of the best niosomal formulation were assessed on MCF-7 cells, using MTT assay.
Results: The optimal niosomal formulation with span 80 and lipid-to-drug molar ratio of 20 was selected, with maximum encapsulation of both drugs and minimum size. Drug release behavior at physiological pH (7.4) (with significant drug release under acidic conditions (pH = 5) and storage stability of up to 2 weeks with little change in drug efficacy and measurement makes it a proper candidate for breast cancer treatment.
Conclusion: Finally, the results of this study showed the importance of creating highly biocompatible formulations, allowing the simultaneous transfer of two drugs with controlled release to cancer cells which could improve the chemotherapy process with the synergistic effect of the two drugs.
- Tamoxifen
- Curcumin
- Breast cancer
- coadministration
How to Cite
References
Sebak, S., Novel Nanoparticles for Breast Cancer Targeted Delivery: Preparation and in Vitro Characterization. 2009, McGill University.
Okamoto, Y., et al., Metabolomic analysis uncovered an association of serum phospholipid levels with estrogen-induced mammary tumors in female ACI/Seg rats. Toxicology letters, 2018. 288: p. 65-70.
Carafa, M., E. Santucci, and G. Lucania, Lidocaine-loaded non-ionic surfactant vesicles: characterization and in vitro permeation studies. International journal of pharmaceutics, 2002. 231(1): p. 21-32.
Mansoori, G.A., et al., Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead. World Review of Science, Technology and Sustainable Development, 2007. 4(2): p. 226.
Perou, C.M., et al., Molecular portraits of human breast tumours. nature, 2000. 406(6797): p. 747-752.
Jana, S., B. Chakravarty, and K. Chaudhury, Letrozole and curcumin loaded-PLGA nanoparticles: a therapeutic strategy for endometriosis. J. Nanomed. Biotherap. Discov, 2014. 4(123): p. 10.4172.
Maheshwari, R.K., et al., Multiple biological activities of curcumin: a short review. Life sciences, 2006. 78(18): p. 2081-2087.
Kim, L.A., et al., Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Investigative ophthalmology & visual science, 2014. 55(8): p. 4747-4758.
Ghafelehbashi, R., et al., Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. International journal of pharmaceutics, 2019. 569: p. 118580.
Alemi, A., et al., Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. Journal of nanobiotechnology, 2018. 16(1): p. 28.
Rochdy Haj-Ahmad, R., A. Ali Elkordy, and C. Shu Chaw, In vitro characterisation of Span™ 65 niosomal formulations containing proteins. Current drug delivery, 2015. 12(5): p. 628-639.
Junyaprasert, V.B., et al., Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. International journal of pharmaceutics, 2012. 423(2): p. 303-311.
Manosroi, A. and K. Bauer, The entrapment of a human insulin-DEAE dextran complex in different compound liposomes. Drug Development and Industrial Pharmacy, 1989. 15(14-16): p. 2531-2546.
Rinaldi, F., et al., pH-sensitive niosomes: Effects on cytotoxicity and on inflammation and pain in murine models. Journal of enzyme inhibition and medicinal chemistry, 2017. 32(1): p. 538-546.
Sadeghi, S., et al., Design and Physicochemical Characterization of Lysozyme Loaded Niosomal Formulations as a New Controlled Delivery System. Pharmaceutical Chemistry Journal, 2020: p. 1-10.
Balasubramaniam, A., V. Anil Kumar, and K. Sadasivan Pillai, Formulation and in vivo evaluation of niosome-encapsulated daunorubicin hydrochloride. Drug development and industrial pharmacy, 2002. 28(10): p. 1181-1193.
Lawrence, M., et al., The formation, characterization and stability of non-ionic surfactant vesicles. STP pharma sciences, 1996. 6(1): p. 49-60.
Seras-Cansell, M., M. Ollivon, and S. Lesieur, Generation of non-ionic monoalkyl amphiphile-cholesterol vesicles: evidence of membrane impermeability to octyl glucoside. STP pharma sciences, 1996. 6(1): p. 12-20.
Shaker, D.S., M.A. Shaker, and M.S. Hanafy, Cellular uptake, cytotoxicity and in-vivo evaluation of Tamoxifen citrate loaded niosomes. International journal of pharmaceutics, 2015. 493(1-2): p. 285-294.
Ullah, S., et al., Creatinine-based non-phospholipid vesicular carrier for improved oral bioavailability of Azithromycin. Drug development and industrial pharmacy, 2017. 43(6): p. 1011-1022.
Shilakari Asthana, G., P.K. Sharma, and A. Asthana, In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica, 2016. 2016.
Abbasalipourkabir, R., A. Salehzadeh, and R. Abdullah, Tamoxifen-loaded solid lipid nanoparticles-induced apoptosis in breast cancer cell lines. Journal of experimental nanoscience, 2016. 11(3): p. 161-174.
- Abstract Viewed: 905 times
- PDF Downloaded: 417 times